| P50 | author | Morie A Gertz | Q57052163 |
| | S. Vincent Rajkumar | Q61123608 |
| | Robert A Kyle | Q66385695 |
| | Martha Q Lacy | Q66419394 |
| | Shaji K Kumar | Q85960198 |
| | Francis K Buadi | Q88774336 |
| | Suzanne R Hayman | Q96475488 |
| | Steven R Zeldenrust | Q96475494 |
| | Shirshendu Sinha | Q114300419 |
| | Angela Dispenzieri | Q37838558 |
| P2093 | author name string | Nelson Leung | |
| | Tow Tan | |
| P2860 | cites work | Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease | Q46775156 |
| | Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. | Q51389775 |
| | Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. | Q53497164 |
| | Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis | Q58853178 |
| | Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response | Q60976697 |
| | Amyloidosis | Q60976734 |
| | Response rates and survival in primary systemic amyloidosis | Q68178951 |
| | Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains | Q28219000 |
| | Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation | Q33292965 |
| | Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. | Q33939907 |
| | Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis | Q34176563 |
| | Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy | Q34208267 |
| | Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. | Q34311781 |
| | Primary systemic amyloidosis: clinical and laboratory features in 474 cases. | Q34320169 |
| | Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice | Q34404023 |
| | Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. | Q34437074 |
| | Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis | Q34482518 |
| | International uniform response criteria for multiple myeloma. | Q34549410 |
| | Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant | Q34753416 |
| | International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders | Q34884527 |
| | Stem cell transplantation for the management of primary systemic amyloidosis | Q35012959 |
| | "Primary" systemic amyloidosis and myeloma. Discussion of relationship and review of 81 cases | Q35319855 |
| | Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. | Q35848844 |
| | Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation | Q35849610 |
| | Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis | Q35886289 |
| | Amyloidosis: diagnosis and management | Q36341858 |
| | Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). | Q37045900 |
| | Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain | Q37284404 |
| | Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis | Q43189700 |
| | Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis | Q43762385 |
| P433 | issue | 3 | |
| P921 | main subject | AL amyloidosis | Q4652470 |
| P304 | page(s) | 251-255 | |
| P577 | publication date | 2011-02-15 | |
| P1433 | published in | American Journal of Hematology | Q4744246 |
| P1476 | title | Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis | |
| P478 | volume | 86 | |